Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type

Hisayuki Yokoyama, Joji Yamamoto, Yasuo Tohmiya, Minami F. Yamada, Hiroto Ohguchi, Yasushi Ohnishi, Yoko Okitsu, Noriko Fukuhara, Rie Ohba-Ohtsuka, Katsura Kohata, Kenichi Ishizawa, Junichi Kameoka, Hideo Harigae

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)

Abstract

The prognosis of advanced extranodal NK/T cell lymphoma (ENKTL) is poor. Allogeneic hematopoietic stem cell transplant (allo-HSCT) has been suggested to be a promising treatment for this disease, but its utility has yet to be established. Here we retrospectively analyzed five cases of ENKTL treated with allo-HSCT in our institute. After induction chemotherapy, disease status at allo-HSCT was second CR in three patients and refractory in two patients. All patients received a myeloablative conditioning regimen, and GVHD prophylaxis consisted of tacrolimus or cyclosporine with short-term methotrexate. Only one patient who received conventional induction chemotherapy developed severe complications, which needed long-term treatment, while others who received chemotherapy containing l-asparaginase did not have severe complications. There were no cases of treatment-related mortality, and all patients survived without disease for a median follow-up period of 1911 days. These results suggested that allo-HSCT following l-asparaginase-containing induction chemotherapy might improve the outcome of advanced ENKTL.

Original languageEnglish
Pages (from-to)1509-1512
Number of pages4
JournalLeukemia and Lymphoma
Volume51
Issue number8
DOIs
Publication statusPublished - 2010 Aug

Keywords

  • Allogeneic hematopoietic stem cell transplant
  • extranodal NK/T cell lymphoma nasal type
  • l-asparaginase

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type'. Together they form a unique fingerprint.

Cite this